Scalp cooling device for prevention of alopecia

Phase 2

• Conditions: Breast Cancer; D001943

• Registration Number: JPRN-jRCTs022190002
• Lead Sponsor: Hirano Akira

Brief Summary

Success rate of hair preservation was 40% (8/20). Hair loss of all patients recovered after 6 months., suggesting that scalp cooling with Paxman was effective for hair preservation. from anthracyclines and taxanes.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-29
• Study Completion: 2020-07-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 22

Inclusion Criteria

1) Diagnosed as primary breast cancer (Stage I to III)
2) Patients scheduled to receive preoperative or postoperative adjuvant chemotherapy containing anthracycline and/or taxanes

Exclusion Criteria

1) Patients with blood malignancy
2) cold allergy

Study & Design

• Study Type: Interventional
• Study Design: Not specified